Related Experiment Video
Updated: May 13, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies
Dalia L Rotstein1, Sheliza Halani1, Peter Vadas1
1Department of Medicine, University of Toronto, Toronto, ON, Canada; St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
Background:
Enteroviral encephalitis is a rare but potentially devastating infectious complication described under the anti-CD20 therapies rituximab and ocrelizumab.
Case:
A 37-year-old woman with multiple sclerosis (MS) on treatment with ofatumumab developed fever, confusion, seizures, and decreased level of consciousness. Magnetic resonance imaging (MRI) revealed bilateral, non-enhancing thalamic T2 hyperintensities, and cerebrospinal fluid showed pleocytosis with positive polymerase chain reaction (PCR) for enterovirus. The patient was treated with intravenous immunoglobulin and supportive care, and then pocapavir was given for ongoing neurologic deficits. She recovered over 6 weeks but continued to demonstrate neuropsychiatric symptoms.
Conclusion:
Enteroviral encephalitis is associated with anti-CD20 therapies for MS as a class effect including ofatumumab.
More Related Videos
06:03Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
Published on: September 20, 2024
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Related Concept Videos
Encephalitis ll: Pathophysiology
Arboviral Encephalitis
Cytomegalovirus Disease
Encephalitis l: Introduction
Cytotoxic Edema: Pathophysiology
Hypersensitivity Reactions: Cytolytic Reactions